RETATRUTIDE 30mg

Price range: R1 600,00 through R2 000,00

Retatrutide

What it is: An investigational once-weekly peptide medicine developed by Eli Lilly. It is a triple hormone-receptor agonist, activating GIP, GLP-1, and glucagon receptors.
Commonly studied/marketed for: Primarily weight loss and obesity management, with clinical trials also investigating type 2 diabetes and obesity-related conditions.
How it works: The combined GIP, GLP-1, and glucagon activity is intended to reduce appetite and food intake while affecting glucose metabolism and energy expenditure. This differs from semaglutide (GLP-1) and tirzepatide (GIP/GLP-1).
Evidence: Strong and rapidly developing human clinical evidence. In the original Phase 2 obesity trial, the 12 mg group had an average 24.2% reduction in body weight at 48 weeks. More recent Phase 3 results have also reported substantial weight loss, including up to 20.8% at 80 weeks in participants with obesity/overweight and type 2 diabetes.
Key risks/side effects: Gastrointestinal effects such as nausea, diarrhea and vomiting have been reported. Clinical studies have also observed dose-related increases in heart rate. Because development is ongoing, the complete long-term safety profile is not yet established.
Regulatory status: Not currently approved by any regulatory agency. As of September 2026, retatrutide remains investigational and is available legally only through clinical trials. Lilly has stated that it plans to submit a U.S. Biologics License Application in Q1 2027.
Bottom line: Retatrutide is a next-generation triple agonist with substantial clinical weight-loss results, but it remains an investigational medicine. Products sold outside legitimate clinical trials cannot be assumed to contain genuine retatrutide or have verified purity, concentration, or sterility.

SKU: RETA Category: WEIGHT MANAGEMENT Tags: appetite, body-weight management, cardiometabolic health, glp, glp-1, glucagon, hunger management, regulation, ret, reta, retatru, supression, triple-hormone receptor agonist

Description

RETATRUTIDE – ADVANCED METABOLIC RESEARCH PEPTIDE

Elevate Wellness Hub’s Retatrutide is an investigational triple-hormone receptor agonist designed to activate the GIP, GLP-1, and glucagon receptor pathways. It is being studied extensively for its potential role in metabolic health, body-weight management, and glucose regulation.

KEY BENEFITS

Supports research into metabolic health and energy regulation
Investigated for body-weight management
Supports research into glucose and glycemic regulation
Activates three complementary metabolic hormone pathways
Being studied in obesity and related metabolic conditions
Investigated for potential benefits across cardiometabolic health

WHO MAY BENEFIT?

Retatrutide is currently an investigational medicine and is being studied in adults with obesity or overweight, including people with certain weight-related metabolic conditions and type 2 diabetes. It is not currently approved for general public use and should only be accessed through an appropriate clinical-trial or regulatory pathway.

HOW IT MAY HELP

Activates the GLP-1 receptor pathway, which plays an important role in appetite and glucose regulation
Activates the GIP receptor pathway, involved in metabolic and insulin-related signalling
Activates the glucagon receptor pathway, which influences energy metabolism
The combination of these three pathways is being investigated as a novel approach to metabolic health
Phase 3 clinical trials have reported significant reductions in body weight and improvements in glycemic measures in studied populations.

POSSIBLE SIDE EFFECTS

Clinical trials have reported gastrointestinal and other adverse effects associated with retatrutide. Potential effects may include:

Nausea
Diarrhea
Vomiting
Constipation
Reduced appetite
Abdominal discomfort
Fatigue
Injection-site reactions

NOT SUITABLE FOR

Pregnancy or breastfeeding
Children unless specifically directed within an appropriate specialist setting or clinical trial
Anyone with a known allergy or sensitivity to the ingredients
Individuals with significant medical conditions without appropriate healthcare supervision
Anyone using other metabolic, glucose-lowering, or weight-management medicines without professional medical guidance
Anyone seeking an unapproved alternative to established medical treatment

IMPORTANT DISCLAIMER

Retatrutide is an investigational medicine and is not currently approved by the FDA or any other regulatory agency for general public use. It remains under clinical investigation, including Phase 3 studies. Elevate Wellness Hub does not represent Retatrutide as an approved treatment or as a substitute for approved medical therapy. Any use must comply with applicable laws and regulations and be undertaken only under appropriate qualified healthcare-professional supervision or within an authorised clinical-trial setting.

Important: Retatrutide sold outside authorised clinical-trial or regulatory pathways cannot be assumed to have verified identity, purity, strength, sterility, or safety.

It’s not just about feeling better, it’s about elevating your quality of life.

ELEVATE WELLNESS HUB – PEPTIDE WELLNESS – SCIENCE BACKED. RESULTS DRIVEN. YOU ELEVATED.

Additional information

Weight	N/A
Type	VILE, PEN

Reviews

There are no reviews yet.

Be the first to review “RETATRUTIDE 30mg”